Physician profile
Megan E Cannon
NPI 1326459470
$3,536.89
in general payments reported to CMS, 2019-2025
35 companies · $1,779 in 2025
The $1,779 reported for 2025 was more than what 94% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $190 · 2020: $163 · 2021: $192 · 2022: $451 · 2023: $385 · 2024: $378 · 2025: $1,779.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $1,500 · Food and Beverage: $1,042.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $1,500.00 |
| Food and Beverage | $1,041.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $1,515.59 | 2024-2025 | |
| Hologic Sales and Service, LLC | $397.41 | 2019-2025 | Acessa Provu System, Sonata Sonography-Guided Transcervical Fibroid Ablation System, Myosure Tissue Removal Device |
| Abbvie INC. | $388.35 | 2019-2025 | Liletta, Lo Loestrin Fe |
| Bayer Healthcare Pharmaceuticals INC. | $180.37 | 2019-2023 | |
| Organon LLC | $148.23 | 2022-2024 | Nexplanon |
| Merck Sharp & Dohme LLC | $134.48 | 2022-2024 | Gardasil 9, Gardasil |
| Exeltis, USA INC. | $87.73 | 2020-2025 | Slynd |
| Coopersurgical, INC. | $67.95 | 2021-2023 | Paragard T 380a |
| Sumitomo Pharma America, INC. | $55.67 | 2023-2025 | Myfembree |
| Therapeuticsmd, INC. | $48.49 | 2019-2021 | |
| Astellas Pharma US INC | $46.41 | 2023-2024 | Veozah |
| Coloplast Corp | $41.03 | 2024 | |
| Avion Pharmaceuticals | $35.00 | 2021-2022 | |
| Convatec INC. | $28.31 | 2023 | |
| Shield Therapeutics INC | $23.92 | 2024 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Caris Mpi, INC. | $22.09 | 2025 | Mi Cancer Seek |
| Dilon Technologies, INC. | $21.95 | 2025 | Hemoblast Bellows |
| Cepheid | $20.64 | 2024 | |
| Ibsa Pharma INC. | $20.48 | 2024 | Tirosint, Licart |
| Medicem INC. | $19.00 | 2023 | |
| Daiichi Sankyo INC. | $18.88 | 2020 | |
| Amgen INC. | $18.76 | 2022 | |
| Evofem Biosciences, INC. | $18.28 | 2021 | |
| Roche Diagnostics Corporation | $18.28 | 2021 | |
| Pacira Pharmaceuticals Incorporated | $18.07 | 2021 | |
| Ascend Therapeutics US, LLC | $16.25 | 2022 | |
| Myovant Sciences INC. | $15.77 | 2021 | |
| Pfizer INC. | $15.23 | 2021 | |
| Agile Therapeutics, INC. | $14.82 | 2023 | Twirla |
| Allergan, INC. | $14.75 | 2019 | |
| Lupin INC. | $14.00 | 2020 | |
| Mayne Pharma Commercial LLC | $13.79 | 2025 | |
| Idorsia Pharmaceuticals US INC | $13.09 | 2024 | Quviviq |
| Amag Pharmaceuticals, INC. | $12.52 | 2019 | |
| Ethicon US, LLC | $11.30 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Megan Cannon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.